New scientific advances in gastroenterology presented at college's 68th annual meeting
October 08, 2003WASHINGTON, DC (October 13, 2003) - Several of the world's preeminent gastroenterologists will gather from October 10 - October 15 for the American College of Gastroenterology's (ACG) 68th Annual Scientific Meeting at the Baltimore Convention Center in Baltimore, Maryland. The agenda includes the latest advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.
Scientific presentations at the meeting will focus on new challenges in patient care faced by gastroenterologists and advances in the prevention and treatment of digestive diseases. Highlights of topics to be addressed include:
- Functional Dyspepsia. Two studies characterize people with this disorder. The first finds that a significant portion of Americans suffering from functional dyspepsia also have irritable bowel syndrome (IBS). The second addresses the first detailed study of this disease among African Americans.
- Bone Density and Inflammatory Bowel Disease (IBD). Two studies highlight the role bone density and osteoporosis play in IBD.
- Living Donor Liver Transplantation (LDLT). This study, the largest single-center investigation of LDLT in the United States, suggests that LDLT offers less complications and higher survival rates.
- Diet and GI Disease. Two studies explore the affect of diet (particularly fat and fructose consumption) on dyspepsia and IBS.
- Colorectal Cancer. Several studies at the Meeting explore colon cancer:
- The link between alcohol consumption and colorectal cancer;
- GI doctors' compliance with screening guidelines;
- The importance of screening in women regardless of symptoms;
- The importance of screening in African Americans because of a high prevalence of premalignant polyps; and
- Virtual colonoscopy vs. conventional colonoscopy
- Irritable Bowel Syndrome. Two studies examine the global impact of IBS on business, reviewing its affect on sick days and lower productivity.
- Reflux Disease. This study suggests a causal relationship between GERD and sleep apnea.
- Children and Constipation. This study explores generalized anxiety and defecation anxiety among children.
Two keynote addresses will highlight the program. The J. Edward Berk Distinguished Lecture, "Demystifying Motility: Gut Motor Dysfunction in Clinical Practice," will be delivered by Eamonn M.M. Quigley, M.D., FACG on Tuesday, October 14, 2003, at 10:10 AM (EDT). The Baker Presidential Lecture, "Reducing NSAID-Induced GI Injury: Keeping the GI Home at Night," will be presented by Loren A. Laine, M.D., FACG at 10:15 AM (EDT) on Wednesday, October 15, 2003.
Lunchtime media briefings are planned on the following topics:
Monday, October 13, 2002, 12:30 PM (EDT)
"Translating New Advances into Real Relief for IBS Sufferers"
Call-in number: 1-800-588-5167, access code 9944#
- Lawrence J. Brandt, M.D., MACG, Montefiore Hospital, Bronx, NY
- Kevin W. Olden, M.D., FACG, Mayo Clinic Scottsdale, Scottsdale, AZ
- Yuri Saito, M.D., FACG, Mayo Clinic, Rochester, MN
- Co-Moderator: Philip E. Jaffe, M.D., FACG, University of Connecticut Health Center, Farmington, CT
- Co-Moderator: Prateek Sharma, M.D., FACG, VA Medical Center, Kansas City, MO
"Emerging Technologies in GI Diagnosis & Treatment: New But Improved?"
Call-in number: 1-800-588-5167, access code 9944#
- David R. Cave, M.D., FACG, St. Elizabeth's Medical Center, Brighton, MA
- Douglas K. Rex, M.D., FACG, Indiana University Hospital, Indianapolis, IN
- Co-Moderator: Beth Schorr-Lesnick M.D., FACG
- Co-Moderator: Girish Mishra, M.D., Wake Forest University School of Medicine, Winston-Salem, NC
Monday, October 13, 2003, 3:30 PM (EDT)
"Emerging Data on NSAIDs, GI Complications & Implications for Clinical Practice"
- David Y. Graham, M.D., MACG, Baylor College of Medicine and VA Medical Center, Houston, TX
- Jay L. Goldstein, M.D., FACG, University of Illinois, Chicago, IL
-end-
The ACG was formed in 1932 to advance the scientific study and medical treatment of disorders of the gastrointestinal (GI) tract. The College promotes the highest standards in medical education and is guided by its commitment to meeting the needs of clinical gastroenterology practitioners. Consumers can get more information on GI diseases through the following ACG-sponsored programs:- 1-800-978-7666 (free brochures on common GI disorders, including ulcer, colon cancer, gallstones, and liver disease)
- 1-866-IBS-RELIEF and www.ibsrelief.org (free educational materials)
- 1-800-HRT-BURN (free brochure and video on heartburn and GERD)
- www.acg.gi.org (ACG's Web site)
American College of Gastroenterology
Related Irritable Bowel Syndrome Articles from Brightsurf:
Giant spider provides promise of pain relief for irritable bowel syndrome
Molecules from the venom of one of the world's largest spiders could help University of Queensland-led researchers tailor pain blockers for people with irritable bowel syndrome (IBS).
An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.
Mindfulness program may benefit patients with irritable bowel syndrome
Adults with irritable bowel syndrome experienced fewer gastrointestinal symptoms after they participated in a mindfulness program meant to reduce stress.
The Lancet Gasteroenterology & Hepatology: First clinical trial finds probiotic treatment with dead bacteria is better than placebo at alleviating symptoms of irritable bowel syndrome
Probiotic bacteria that have been killed by heat can significantly improve symptoms of irritable bowel syndrome (IBS) compared to placebo, and are not associated with any safety risk, according to a new 12-week, randomized, double-blind, placebo-controlled clinical trial with 443 patients published in The Lancet Gastroenterology & Hepatology journal.
Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.
New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.
HKBU discovers mechanisms underlying early life stress and irritable bowel syndrome
Researchers from Hong Kong Baptist University have found that the abnormal rise of a soluble protein called Nerve Growth Factor is a key factor linking early life stress to the development of irritable bowel syndrome.
Microbiome science may help doctors deliver more effective, personalized treatment to children with irritable bowel syndrome
To improve the treatment of children with irritable bowel syndrome (IBS), investigators have developed a sophisticated way to analyze the microbial and metabolic contents of the gut.
The Lancet Gastroenterology & Hepatology: Hypnotherapy could help relieve irritable bowel syndrome symptoms
Peer-reviewed / Randomised Controlled Trial / People Gut-directed hypnotherapy delivered by psychologists appears as effective in group or individual sessions, potentially offering a new treatment option for irritable bowel syndrome in primary and secondary care
Early source of irritable bowel syndrome discovered
Michigan State University scientists have identified an early cause of intestinal inflammation, one of the first stages of inflammatory bowel disease and irritable bowel syndrome, which afflict around 11 percent of the world's population.
Read More: Irritable Bowel Syndrome News and Irritable Bowel Syndrome Current Events
Molecules from the venom of one of the world's largest spiders could help University of Queensland-led researchers tailor pain blockers for people with irritable bowel syndrome (IBS).
An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.
Mindfulness program may benefit patients with irritable bowel syndrome
Adults with irritable bowel syndrome experienced fewer gastrointestinal symptoms after they participated in a mindfulness program meant to reduce stress.
The Lancet Gasteroenterology & Hepatology: First clinical trial finds probiotic treatment with dead bacteria is better than placebo at alleviating symptoms of irritable bowel syndrome
Probiotic bacteria that have been killed by heat can significantly improve symptoms of irritable bowel syndrome (IBS) compared to placebo, and are not associated with any safety risk, according to a new 12-week, randomized, double-blind, placebo-controlled clinical trial with 443 patients published in The Lancet Gastroenterology & Hepatology journal.
Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.
New, noninvasive test for bowel diseases
Gut diseases such as inflammatory bowel disease (IBD) are increasingly prevalent worldwide, especially in industrialized countries.
HKBU discovers mechanisms underlying early life stress and irritable bowel syndrome
Researchers from Hong Kong Baptist University have found that the abnormal rise of a soluble protein called Nerve Growth Factor is a key factor linking early life stress to the development of irritable bowel syndrome.
Microbiome science may help doctors deliver more effective, personalized treatment to children with irritable bowel syndrome
To improve the treatment of children with irritable bowel syndrome (IBS), investigators have developed a sophisticated way to analyze the microbial and metabolic contents of the gut.
The Lancet Gastroenterology & Hepatology: Hypnotherapy could help relieve irritable bowel syndrome symptoms
Peer-reviewed / Randomised Controlled Trial / People Gut-directed hypnotherapy delivered by psychologists appears as effective in group or individual sessions, potentially offering a new treatment option for irritable bowel syndrome in primary and secondary care
Early source of irritable bowel syndrome discovered
Michigan State University scientists have identified an early cause of intestinal inflammation, one of the first stages of inflammatory bowel disease and irritable bowel syndrome, which afflict around 11 percent of the world's population.
Read More: Irritable Bowel Syndrome News and Irritable Bowel Syndrome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.